The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
Understanding and overcoming metformin gastrointestinal intolerance
Abstract
Metformin is the most widely prescribed drug for patients with type 2 diabetes mellitus and the first‐line pharmacological option as supported by multiple international guidelines, yet a rather large proportion of patients cannot tolerate metformin in adequate amounts because of its associated gastrointestinal ( GI ) adverse events ( AEs ). GI AEs typically encountered with metformin therapy include diarrhoea, nausea, flatulence, indigestion, vomiting and abdominal discomfort, with diarrhoea and nausea being the most common. Although starting at a low dose and titrating slowly may help prevent some GI AEs associated with metformin, some patients are unable to tolerate metformin at all and it may also be difficult to convince patients to start metformin again after a bout of GI AEs . Despite this clinical importance, the underlying mechanisms of the GI intolerance associated with metformin are poorly known. In the present review, we discuss: the epidemiology of metformin‐associated GI intolerance and its underlying mechanisms; genotype variability and associated factors affecting metformin GI intolerance, such as comorbidities, co‐medications and bariatric surgery; clinical consequences and therapeutic strategies to overcome metformin GI intolerance. These strategies include appropriate titration of immediate‐release metformin, use of extended‐release metformin, the promise of delayed‐release metformin and gut microbiome modulators, as well as alternative pharmacological therapies when metformin cannot be tolerated at all. Given the available data, all efforts should be made to maintain metformin before considering a shift to another drug therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Sulphonylurea monotherapy for patients with type 2 diabetes mellitus
Hemmingsen, B., Schroll, J. B., Lund, S. S., Wetterslev, J., Gluud, C. N., Vaag, A. A., Sonne, D. P., Lundstrøm, L. H., & Almdal, T. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009008.pub2 · Cited by 90
RetractedInternational Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota
MetaHIT consortium, Forslund, K., Hildebrand, F., Nielsen, T., Falony, G., Le Chatelier, E., Sunagawa, S., Prifti, E., Vieira-Silva, S., Gudmundsdottir, V., et al. (2015) · Nature · doi:10.1038/nature15766 · Cited by 2,116
Cellular and molecular mechanisms of metformin: an overview
Viollet, B., Guigas, B., Garcia, N. S., Leclerc, J., Foretz, M., & Andreelli, F. (2012) · Clinical Science · doi:10.1042/cs20110386 · Cited by 1,720
Shin, N.-R., Lee, J.-C., Lee, H.-Y., Kim, M.-S., Whon, T. W., Lee, M.-S., & Bae, J.-W. (2014) · Gut · doi:10.1136/gutjnl-2012-303839 · Cited by 1,550
Metformin: from mechanisms of action to therapies
Foretz, M., Guigas, B., Bertrand, L., Pollak, M., & Viollet, B. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.09.018 · Cited by 1,501
Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus
DeFronzo, R. A., & Goodman, A. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330902 · Cited by 1,368
Clinical pharmacokinetics of metformin
Graham, G. G., Punt, J., Arora, M., Day, R. O., Doogue, M. P., Duong, J. K., Furlong, T. J., Greenfield, J. R., Greenup, L. C., Kirkpatrick, C. M., et al. (2011) · Clinical Pharmacokinetics · doi:10.2165/11534750-000000000-00000 · Cited by 1,318
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2016) · Endocrine Practice · doi:10.4158/ep151126.cs · Cited by 878
Metformin and the gastrointestinal tract
McCreight, L. J., Bailey, C. J., & Pearson, E. R. (2016) · Diabetologia · doi:10.1007/s00125-015-3844-9 · Cited by 733
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetologia · doi:10.1007/s00125-014-3460-0 · Cited by 694
Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2650 · Cited by 682
Clinical Pharmacokinetics of Metformin
Scheen, A. J. (1996) · Clinical Pharmacokinetics · doi:10.2165/00003088-199630050-00003 · Cited by 636
Self-citationMetformin: An Old But Still the Best Treatment for Type 2 Diabetes
Rojas, L. B. A., & Gomes, M. B. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-6 · Cited by 567
Efficacy of Metformin in Type II Diabetes
Garber, A. J., Duncan, T. G., Goodman, A. M., Mills, D. J., & Rohlf, J. L. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)00254-4 · Cited by 519
Metformin kinetics in healthy subjects and in patients with diabetes mellitus.
Tucker, G., Casey, C., Phillips, P., Connor, H., Ward, J., & Woods, H. (1981) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1981.tb01206.x · Cited by 497
Molecular mechanism of action of metformin: old or new insights?
Rena, G., Pearson, E. R., & Sakamoto, K. (2013) · Diabetologia · doi:10.1007/s00125-013-2991-0 · Cited by 479
Tzoulaki, I., Molokhia, M., Curcin, V., Little, M. P., Millett, C. J., Ng, A., Hughes, R. I., Khunti, K., Wilkins, M. R., Majeed, A., et al. (2009) · BMJ · doi:10.1136/bmj.b4731 · Cited by 444
Palmer, S. C., Mavridis, D., Nicolucci, A., Johnson, D. W., Tonelli, M., Craig, J. C., Maggo, J., Gray, V., De Berardis, G., Ruospo, M., et al. (2016) · JAMA · doi:10.1001/jama.2016.9400 · Cited by 420
Clinical Outcomes and Adherence to Medications Measured by Claims Data in Patients With Diabetes
Pladevall, M., Williams, L. K., Potts, L. A., Divine, G., Xi, H., & Elston Lafata, J. (2004) · Diabetes Care · doi:10.2337/diacare.27.12.2800 · Cited by 404
Effect of Metformin on Metabolic Improvement and Gut Microbiota
Lee, H., & Ko, G. (2014) · Applied and Environmental Microbiology · doi:10.1128/aem.01357-14 · Cited by 385
Umpierrez, G., Tofé Povedano, S., Pérez Manghi, F., Shurzinske, L., & Pechtner, V. (2014) · Diabetes Care · doi:10.2337/dc13-2759 · Cited by 341
Buse, J. B., DeFronzo, R. A., Rosenstock, J., Kim, T., Burns, C., Skare, S., Baron, A., & Fineman, M. (2016) · Diabetes Care · doi:10.2337/dc15-0488 · Cited by 325
Henry, R. R., Murray, A. V., Marmolejo, M. H., Hennicken, D., Ptaszynska, A., & List, J. F. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2012.02911.x · Cited by 310
Joshi, S. R., Standl, E., Tong, N., Shah, P., Kalra, S., & Rathod, R. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1070827 · Cited by 303
Roumie, C. L., Hung, A. M., Greevy, R. A., Grijalva, C. G., Liu, X., Murff, H. J., Elasy, T. A., & Griffin, M. R. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-9-201211060-00003 · Cited by 300
Novel Gut-Based Pharmacology of Metformin in Patients with Type 2 Diabetes Mellitus
Napolitano, A., Miller, S., Nicholls, A. W., Baker, D., Van Horn, S., Thomas, E., Rajpal, D., Spivak, A., Brown, J. R., & Nunez, D. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100778 · Cited by 282
Dujic, T., Zhou, K., Donnelly, L. A., Tavendale, R., Palmer, C. N. A., & Pearson, E. R. (2015) · Diabetes · doi:10.2337/db14-1388 · Cited by 278
Bailey, C. J., Wilcock, C., & Scarpello, J. H. B. (2008) · Diabetologia · doi:10.1007/s00125-008-1053-5 · Cited by 275
DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials
Scheen, A. J. (2012) · Diabetes & Metabolism · doi:10.1016/j.diabet.2011.11.001 · Cited by 200
Self-citationYang, W., Liu, J., Shan, Z., Tian, H., Zhou, Z., Ji, Q., Weng, J., Jia, W., Lu, J., Liu, J., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70021-4 · Cited by 163
New mechanisms of metformin action: Focusing on mitochondria and the gut
Hur, K. Y., & Lee, M. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12328 · Cited by 161
Effect of metformin on bile salt circulation and intestinal motility in Type 2 diabetes mellitus
Scarpello, J. H. B., Hodgson, E., & Howlett, H. C. S. (1998) · Diabetic Medicine · doi:10.1002/(sici)1096-9136(199808)15:8<651::aid-dia628>3.0.co;2-a · Cited by 160
Sulphonylureas and risk of cardiovascular disease: systematic review and meta‐analysis
Phung, O. J., Schwartzman, E., Allen, R. W., Engel, S. S., & Rajpathak, S. N. (2013) · Diabetic Medicine · doi:10.1111/dme.12232 · Cited by 157
Blonde, L., DAILEY, G. E., Jabbour, S. A., Reasner, C. A., & Mills, D. J. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125003278 · Cited by 157
Shyangdan, D., Uthman, O. A., & Waugh, N. R. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-009417 · Cited by 153
Importance of the intestine as a site of metformin‐stimulated glucose utilization
Bailey, C. J., Mynett, K. J., & Page, T. (1994) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1994.tb13128.x · Cited by 147
Nauck, M., Frid, A., Hermansen, K., Thomsen, A. B., During, M., Shah, N., Tankova, T., Mitha, I., & Matthews, D. R. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12012 · Cited by 144
Dujić, T., Causevic, A., Bego, T., Malenica, M., Velija-Ašimi, Z., Pearson, E. R., & Semiz, S. (2015) · Diabetic Medicine · doi:10.1111/dme.13040 · Cited by 140
Stepensky, D., Friedman, M., Raz, I., & Hoffman, A. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.8.861 · Cited by 137
Tarāsova, L., Kalniņa, I., Geldnere, K., Bumbure, A., Ritenberga, R., Ņikitina-Zaķe, L., Frīdmanis, D., Vaivade, I., Pīrāgs, V., & Kloviņš, J. (2012) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283561666 · Cited by 136
DeFronzo, R. A., Buse, J. B., Kim, T., Burns, C. M., Skare, S., Baron, A., & Fineman, M. S. (2016) · Diabetologia · doi:10.1007/s00125-016-3992-6 · Cited by 136
Wu, D., Li, L., & Liu, C. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12174 · Cited by 133
Schwartz, S. L., Fonseca, V. A., Berner, B., Cramer, M., Chiang, Y.-K., & Lewin, A. J. (2006) · Diabetes Care · doi:10.2337/diacare.29.04.06.dc05-1967 · Cited by 132
Florez, H. J., Luo, J., Castillo-Florez, S., Mitsi, G., Hanna, J., Tamariz, L. J., Palacio, A., Nagendran, S., & Hagan, M. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.03.2128 · Cited by 126
Scheen, J., & BVRE, P. L. (1998) · Drugs · doi:10.2165/00003495-199855020-00004 · Cited by 125
Scheen, A. J. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.978289 · Cited by 120
Self-citationLawerence, D. B., Ragucci, K. R., Long, L. B., Parris, B. S., & Helfer, L. A. (2006) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2006.12.6.466 · Cited by 115
Diarrhea and Metformin in a Diabetic Clinic
Dandona, P., Fonseca, V., Mier, A., & Beckett, A. G. (1983) · Diabetes Care · doi:10.2337/diacare.6.5.472 · Cited by 109
Effect of Gastric Bypass Surgery on the Absorption and Bioavailability of Metformin
Padwal, R. S., Gabr, R. Q., Sharma, A. M., Langkaas, L.-A., Birch, D. W., Karmali, S., & Brocks, D. R. (2011) · Diabetes Care · doi:10.2337/dc10-2140 · Cited by 109
Efficacy and Safety of Acarbose in Metformin-Treated Patients With Type 2 Diabetes
Rosenstock, J., Brown, A., Fischer, J., Jain, A., Littlejohn, T., Nadeau, D., Sussman, A., Taylor, T., Krol, A., & Magner, J. (1998) · Diabetes Care · doi:10.2337/diacare.21.12.2050 · Cited by 93
DPP-4 inhibitors: What may be the clinical differentiators?
Gerich, J. E. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.07.006 · Cited by 93
Reasner, C. A., Olansky, L., Seck, T. L., Williams‐Herman, D., Chen, M., Terranella, L., Johnson‐Levonas, A. O., Kaufman, K. D., & Goldstein, B. J. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01390.x · Cited by 90
Bonora, E., CIGOLINI, M., Bosello, O., Zancanaro, C., Capretti, L., Zavaroni, I., Coscelli, C., & BUTTURINI, U. (1984) · Current Medical Research and Opinion · doi:10.1185/03007998409109558 · Cited by 85
Rebello, C. J., Burton, J. H., Heiman, M. L., & Greenway, F. L. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.08.023 · Cited by 84
Advantages of Extended-Release Metformin in Patients with Type 2 Diabetes Mellitus
Jabbour, S. A., & Ziring, B. S. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.01.2241 · Cited by 84
Burton, J. H., Johnson, M., Johnson, J. L., Hsia, D. S., Greenway, F. L., & Heiman, M. L. (2015) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815577425 · Cited by 81
Donnelly, L. A., Morris, A. D., & Pearson, E. R. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00973.x · Cited by 78
Fujioka, K., Brazg, R. L., Raz, I., Bruce, S., Joyal, S., Swanink, R., & Pans, M. (2005) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2004.00369.x · Cited by 73
Involvement of glucagon‐like peptide‐1 in the glucose‐lowering effect of metformin
Bahne, E., Hansen, M., Brønden, A., Sonne, D. P., Vilsbøll, T., & Knop, F. K. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12697 · Cited by 73
Morgan, C. L., Mukherjee, J., Jenkins‐Jones, S., Holden, S. E., & Currie, C. J. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12302 · Cited by 72
Andújar-Plata, P., Pi-Sunyer, X., & Laferrère, B. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.09.022 · Cited by 69
Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated
Irons, B. K., & Minze, M. G. (2014) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s38753 · Cited by 68
Fixed-Dose Combinations for Treatment of Type 2 Diabetes Mellitus
Blonde, L., & Juan, Z. T. S. (2012) · Advances in Therapy · doi:10.1007/s12325-011-0094-1 · Cited by 65
Scheen, A. J. (2016) · Diabetes & Metabolism · doi:10.1016/j.diabet.2015.12.005 · Cited by 51
Self-citationIncreased F-18 FDG Intestinal Uptake in Diabetic Patients on Metformin
Bybel, B., Greenberg, I. D., Paterson, J., Ducharme, J., & Leslie, W. D. (2011) · Clinical Nuclear Medicine · doi:10.1097/rlu.0b013e318217399e · Cited by 47
Metformin as a Cause of Late‐Onset Chronic Diarrhea
Foss, M. T., & Clement, K. D. (2001) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.21.17.1422.34430 · Cited by 44
Greenway, F. L., Wang, S., & Heiman, M. L. (2013) · Beneficial Microbes · doi:10.3920/bm2012.0063 · Cited by 44
Weng, J., Soegondo, S., Schnell, O., Sheu, W. H., Grzeszczak, W., Watada, H., Yamamoto, N., & Kalra, S. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2576 · Cited by 42
New prolonged-release metformin improves gastrointestinal tolerability
Davidson, J. A., & Howlett, H. C. S. (2004) · The British Journal of Diabetes · doi:10.1177/14746514040040041101 · Cited by 40
Hermans, M. P., Delibaşı, T., Farmer, I., Lohm, L., Maheux, P., Piatti, P., Malvolti, E., Jörgens, S., & Charbonnel, B. H. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.735646 · Cited by 30
Shillington, A. C., Col, N. F., Bailey, R., & Jewell, M. A. (2015) · Patient Preference and Adherence · doi:10.2147/ppa.s82555 · Cited by 24
Huang, Y., Sun, J., Wang, X., Tao, X., Wang, H., & Tan, W. (2014) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0203 · Cited by 24
Ji, L., Pan, C. ‐., Lu, J. ‐., Li, H., Zhu, D., Li, Q., Li, Q., Peng, Y.-L., Tian, H., Yao, C., et al. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12667 · Cited by 24
Weymann, N., Härter, M. C., Petrak, & Dirmaier, J. (2013) · Patient Preference and Adherence · doi:10.2147/ppa.s46924 · Cited by 22
Asymptomatic chronic gastritis decreases metformin tolerance in patients with type 2 diabetes
Huang, Y., Sun, J., Wang, X., Tao, X., Wang, H., & Tan, W. (2015) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12290 · Cited by 20
Chacra, A. R. (2012) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e318235f1bb · Cited by 20
What is the phenotype of patients with gastrointestinal intolerance to metformin?
Hermans, M. P., Ahn, S. A., & Rousseau, M. F. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2013.05.005 · Cited by 18
Hazel-Fernandez, L. A., Xu, Y., Moretz, C., MEAH, Y. A., Baltz, J. C., Lian, J., Kimball, E. S., & Bouchard, J. R. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1067194 · Cited by 16
Guo, L., Guo, X., Yan, L., Xu, H., Jiang, X., Su, Q., Zhao, D., Wu, X., & Ji, L. (2016) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2016.01.004 · Cited by 12
Impact on glycated haemoglobin of a biological response‐based measure of medication adherence
Nichols, G. A., Rosales, A. G., Kimes, T. M., Tunceli, K., Kurtyka, K., Mavros, P., & Steiner, J. F. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12476 · Cited by 11
Pala, L., & Rotella, C. M. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0065-x · Cited by 10
Combination Therapy When Metformin Is Not an Option for Type 2 Diabetes
Goldman, J. D. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015572653 · Cited by 7
New Insight into the Mechanisms of the Anti-hyperglycemic Action of Metformin
Gruszka, A. (2015) · Journal of Advances in Medicine and Medical Research · doi:10.9734/bjmmr/2016/23354 · Cited by 7
Cited by
Metformin: update on mechanisms of action and repurposing potential
Foretz, M., Guigas, B., & Viollet, B. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00833-4 · Cited by 699
Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus
Foretz, M., Guigas, B., & Viollet, B. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0242-2 · Cited by 686
Flory, J., & Lipska, K. (2019) · JAMA · doi:10.1001/jama.2019.3805 · Cited by 453
Shi, Q., Wang, Y., Hao, Q., Vandvik, P. O., Guyatt, G., Li, J., Chen, Z., Xu, S., Shen, Y., Ge, L., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)01640-8 · Cited by 279
RetractedShi, Q., Wang, Y., Hao, Q., Vandvik, P. O., Guyatt, G., Li, J., Chen, Z., Xu, S., Shen, Y., Ge, L., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00351-9 · Cited by 155
Metadata
- Authors
- Bonnet, F., & Scheen, A.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2017-02-22
- Volume
- 19
- Issue
- 4
- Pages
- 473-481
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2567000504
- Cited by
- 256
- References
- 91
- FWCI
- 9.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.